Neurogene Inc.
NGNEHealthcare|Biotechnology|US
$25.31
-0.34 (-1.33%)
DCF Value
$4.36
Tangible Book / Share
$9.63
Cash / Share
$9.99
Ownership Breakdown
79.3%
Float
15.8M
Shares Outstanding
12.5M
Float Shares
Major Holders (39)
Combined: 259.2%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Dr. Srinivas Akkaraju | Individual | 11.60% | 1,717,127 | Nov 27, 2024 | 13D/G |
| Samsara BioCapital GP, LLC | Other | 11.60% | 1,717,127 | Nov 27, 2024 | 13D/G |
| Samsara BioCapital, L.P. | Partnership | 11.60% | 1,717,127 | Nov 27, 2024 | 13D/G |
| Prudential Financial Inc | Holding company | 11.20% | 2,231,357 | Oct 7, 2026 | 13D/G |
| Jennison Associates LLC | Investment adviser | 11.10% | 2,229,082 | Oct 6, 2026 | 13D/G |
| RTW Investments, LP | IA, PN | 9.99% | 1,498,829 | Feb 14, 2025 | 13D/G |
| Roderick Wong, M.D. | HC, IN | 9.99% | 1,498,829 | Feb 14, 2025 | 13D/G |
| Redmile Group, LLC | IA, OO | 9.90% | 1,572,202 | Aug 14, 2026 | 13D/G |
| Jeremy C. Green | HC, IN | 9.90% | 1,572,202 | Aug 14, 2026 | 13D/G |
| Oleg Nodelman | HC, IN | 9.90% | 1,442,902 | Nov 14, 2025 | 13D/G |
| EcoR1 Capital, LLC | IA, OO | 9.90% | 1,442,902 | Nov 14, 2025 | 13D/G |
| Eli Casdin | HC, IN | 8.70% | 1,295,361 | Feb 14, 2025 | 13D/G |
| Casdin Capital, LLC | Investment adviser | 8.70% | 1,295,361 | Feb 14, 2025 | 13D/G |
| EcoR1 Capital Fund Qualified, L.P. | Partnership | 8.60% | 1,249,344 | Nov 14, 2025 | 13D/G |
| Casdin Partners Master Fund, L.P. | Partnership | 7.20% | 1,075,000 | Feb 14, 2025 | 13D/G |
| Casdin Partners GP, LLC | Other | 7.20% | 1,075,000 | Feb 14, 2025 | 13D/G |
| Baker Bros. Advisors (GP) LLC | HC, OO | 7.00% | 991,691 | Aug 14, 2025 | 13D/G |
| Julian C. Baker | HC, IN | 7.00% | 991,804 | Aug 14, 2025 | 13D/G |
| Felix J. Baker | HC, IN | 7.00% | 991,804 | Aug 14, 2025 | 13D/G |
| Baker Bros. Advisors LP | IA, PN | 7.00% | 991,691 | Aug 14, 2025 | 13D/G |
| BlackRock, Inc. | Holding company | 6.80% | 1,011,436 | Apr 23, 2025 | 13D/G |
| Dmitry Balyasny | HC, IN | 5.18% | 818,706 | Aug 14, 2026 | 13D/G |
| Bam GP LLC | HC, OO | 5.18% | 818,706 | Aug 14, 2026 | 13D/G |
| Balyasny Asset Management Holdings LP | HC, PN | 5.18% | 818,706 | Aug 14, 2026 | 13D/G |
| Dames GP LLC | HC, OO | 5.18% | 818,706 | Aug 14, 2026 | 13D/G |
| Balyasny Asset Management L.P. | IA, PN | 5.18% | 818,706 | Aug 14, 2026 | 13D/G |
| Redmile Biopharma Investments I, L.P. | Partnership | 5.10% | 812,033 | Aug 14, 2026 | 13D/G |
| Trails Edge Capital Partners, LP | IA, PN | 4.50% | 714,885 | Aug 14, 2026 | 13D/G |
| Trails Edge Biotechnology Master Fund, LP | Partnership | 4.50% | 714,885 | Aug 14, 2026 | 13D/G |
| Ortav Yehudai | Individual | 4.50% | 714,885 | Aug 14, 2026 | 13D/G |
| Abigail P. Johnson | Individual | 3.10% | 462,879 | May 12, 2025 | 13D/G |
| FMR LLC | Holding company | 3.10% | 462,879 | May 12, 2025 | 13D/G |
| Commodore Capital LP | IA, PN | 3.00% | 427,866 | Aug 14, 2025 | 13D/G |
| Commodore Capital Master LP | Partnership | 3.00% | 427,866 | Aug 14, 2025 | 13D/G |
| Great Point Partners, LLC | IA, OO | 2.98% | 442,761 | Feb 14, 2025 | 13D/G |
| Dr. Jeffrey R. Jay, M.D. | HC, IN | 2.98% | 442,761 | Feb 14, 2025 | 13D/G |
| Ms. Lillian Nordahl | HC, IN | 2.98% | 442,761 | Feb 14, 2025 | 13D/G |
| Bihua Chen | Individual | 0.83% | 107,344 | Nov 14, 2024 | 13D/G |
| Cormorant Asset Management, LP | Investment adviser | 0.83% | 107,344 | Nov 14, 2024 | 13D/G |
Insider Trades (79)
Last 4 quarters: 638,450 acquired · 48,377 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| McMinn Rachel | director, officer: Chief Executive Officer | Sep 22, 2026 | OPTION EX. | 756 | $25.32 | $19.1K | Form 4 |
| McMinn Rachel | director, officer: Chief Executive Officer | Sep 22, 2026 | OPTION EX. | 756 | $25.32 | $19.1K | Form 4 |
| Cvijic Christine Mikail | director, officer: President and CFO | Jul 6, 2026 | SELL | 600 | $36.02 | $21.6K | Form 4 |
| Cvijic Christine Mikail | director, officer: President and CFO | Jul 7, 2026 | SELL | 4,200 | $36.13 | $151.8K | Form 4 |
| Cvijic Christine Mikail | director, officer: President and CFO | Jul 1, 2026 | SELL | 739 | $34.06 | $25.2K | Form 4 |
| Cvijic Christine Mikail | director, officer: President and CFO | Jul 2, 2026 | SELL | 2,531 | $34.58 | $87.5K | Form 4 |
| Cvijic Christine Mikail | director, officer: President and CFO | Jul 2, 2026 | SELL | 1,530 | $35.23 | $53.9K | Form 4 |
| Woods Keith | director | Jan 16, 2024 | AWARD | 15,400 | $32.30 | $497.4K | Form 4 |
| Woods Keith | director | Jun 14, 2024 | AWARD | 7,700 | $42.59 | $327.9K | Form 4 |
| Woods Keith | director | Jun 12, 2025 | AWARD | 12,050 | $20.40 | $245.8K | Form 4 |
| Woods Keith | director: | Dec 18, 2023 | OTHER | 0 | — | — | Form 4 |
| Cvijic Christine Mikail | director, officer: President and CFO | May 6, 2026 | SELL | 4,800 | $30.07 | $144.4K | Form 4 |
| Cvijic Christine Mikail | director, officer: President and CFO | May 6, 2026 | SELL | 4,800 | $32.44 | $155.7K | Form 4 |
| Shafer Christina | Chief Commercial Officer | May 5, 2026 | AWARD | 120,000 | $28.94 | $3.5M | Form 4 |
| Shafer Christina | officer | Apr 20, 2026 | OTHER | 0 | — | — | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 26, 2026 | SELL | 2,558 | $21.62 | $55.3K | Form 4 |
| McMinn Rachel | director, officer: Chief Executive Officer | Mar 26, 2026 | SELL | 3,352 | $22.07 | $74.0K | Form 4 |
| Jordan Julie | Chief Medical Officer | Mar 26, 2026 | SELL | 828 | $21.89 | $18.1K | Form 4 |
| Cobb Stuart | Chief Scientific Officer | Mar 13, 2026 | SELL | 3,991 | $20.41 | $81.5K | Form 4 |
| Cobb Stuart | Chief Scientific Officer | Mar 13, 2026 | SELL | 2,658 | $21.34 | $56.7K | Form 4 |
| Cobb Stuart | Chief Scientific Officer | Mar 13, 2026 | SELL | 148 | $22.08 | $3.3K | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 13, 2026 | SELL | 2,387 | $20.42 | $48.7K | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 13, 2026 | SELL | 1,395 | $21.25 | $29.6K | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 13, 2026 | SELL | 263 | $22.02 | $5.8K | Form 4 |
| Cvijic Christine Mikail | President and CFO | Feb 27, 2026 | SELL | 4,800 | $25.11 | $120.5K | Form 4 |
| Cobb Stuart | Chief Scientific Officer | Feb 20, 2026 | AWARD | 16,500 | — | — | Form 4 |
| Jordan Julie | Chief Medical Officer | Feb 20, 2026 | AWARD | 29,600 | $17.64 | $522.1K | Form 4 |
| Jordan Julie | Chief Medical Officer | Feb 20, 2026 | AWARD | 4,900 | — | — | Form 4 |
| Cvijic Christine Mikail | President and CFO | Feb 20, 2026 | AWARD | 131,900 | $17.64 | $2.3M | Form 4 |
| Cvijic Christine Mikail | President and CFO | Feb 20, 2026 | AWARD | 22,000 | — | — | Form 4 |
| McMinn Rachel | director, officer: Chief Executive Officer | Feb 20, 2026 | AWARD | 25,900 | — | — | Form 4 |
| McMinn Rachel | director, officer: Chief Executive Officer | Feb 20, 2026 | AWARD | 155,100 | $17.64 | $2.7M | Form 4 |
| PALEKAR ROHAN | director | Feb 20, 2026 | AWARD | 12,050 | $17.64 | $212.6K | Form 4 |
| BAFFI ROBERT | director | Feb 20, 2026 | AWARD | 12,050 | $17.64 | $212.6K | Form 4 |
| Noonberg Sarah B. | director | Feb 20, 2026 | AWARD | 12,050 | $17.64 | $212.6K | Form 4 |
| Freedland Cory S. | director | Feb 20, 2026 | AWARD | 12,050 | $17.64 | $212.6K | Form 4 |
| Woods Keith | director | Feb 20, 2026 | AWARD | 12,050 | $17.64 | $212.6K | Form 4 |
| BAFFI ROBERT | director | Jun 12, 2025 | AWARD | 12,050 | $20.40 | $245.8K | Form 4 |
| Woods Robert Keith | director | Jun 12, 2025 | AWARD | 12,050 | $20.40 | $245.8K | Form 4 |
| PALEKAR ROHAN | director | Jun 12, 2025 | AWARD | 12,050 | $20.40 | $245.8K | Form 4 |
| Freedland Cory S. | director | Jun 12, 2025 | AWARD | 12,050 | $20.40 | $245.8K | Form 4 |
| Noonberg Sarah B. | director | Jun 12, 2025 | AWARD | 12,050 | $20.40 | $245.8K | Form 4 |
| Cobb Stuart | Chief Scientific Officer | May 14, 2025 | SELL | 6,797 | $15.15 | $103.0K | Form 4 |
| Cobb Stuart | Chief Scientific Officer | Mar 26, 2025 | AWARD | 42,900 | $16.14 | $692.4K | Form 4 |
| Cobb Stuart | Chief Scientific Officer | Mar 26, 2025 | AWARD | 7,200 | — | — | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 26, 2025 | AWARD | 122,000 | $16.14 | $2.0M | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 26, 2025 | AWARD | 20,300 | — | — | Form 4 |
| Jordan Julie | Chief Medical Officer | Mar 26, 2025 | AWARD | 50,300 | $16.14 | $811.8K | Form 4 |
| Jordan Julie | Chief Medical Officer | Mar 26, 2025 | AWARD | 8,400 | — | — | Form 4 |
| McMinn Rachel | director, officer: Chief Executive Officer | Mar 26, 2025 | AWARD | 23,900 | — | — | Form 4 |
| McMinn Rachel | director, officer: Chief Executive Officer | Mar 26, 2025 | AWARD | 143,500 | $16.14 | $2.3M | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 13, 2025 | SELL | 4,501 | $16.94 | $76.2K | Form 4 |
| Samsara BioCapital GP, LLC | 10 percent owner | Nov 26, 2024 | BUY | 2,000 | $27.50 | $55.0K | Form 4 |
| Samsara BioCapital GP, LLC | 10 percent owner | Nov 26, 2024 | BUY | 15,219 | $26.73 | $406.8K | Form 4 |
| Samsara BioCapital GP, LLC | 10 percent owner | Nov 26, 2024 | BUY | 10,803 | $26.01 | $281.0K | Form 4 |
| Samsara BioCapital GP, LLC | 10 percent owner | Nov 26, 2024 | BUY | 20,748 | $24.91 | $516.8K | Form 4 |
| Samsara BioCapital GP, LLC | 10 percent owner | Nov 25, 2024 | OTHER | 0 | — | — | Form 4 |
| Samsara BioCapital GP, LLC | 10 percent owner | Nov 25, 2024 | OTHER | 67,070 | — | — | Form 4 |
| Samsara BioCapital GP, LLC | 10 percent owner | Nov 25, 2024 | OTHER | 20,000 | $0.00 | $20.00 | Form 4 |
| Cvijic Christine Mikail | President and CFO | Nov 22, 2024 | BUY | 24,000 | $20.48 | $491.4K | Form 4 |
| McMinn Rachel | director, officer: Chief Executive Officer | Nov 22, 2024 | BUY | 47,500 | $20.40 | $969.0K | Form 4 |
| Woods Robert Keith | director | Jun 14, 2024 | AWARD | 7,700 | $42.59 | $327.9K | Form 4 |
| PALEKAR ROHAN | director | Jun 14, 2024 | AWARD | 7,700 | $42.59 | $327.9K | Form 4 |
| BAFFI ROBERT | director | Jun 14, 2024 | AWARD | 7,700 | $42.59 | $327.9K | Form 4 |
| Noonberg Sarah B. | director | Jun 14, 2024 | AWARD | 7,700 | $42.59 | $327.9K | Form 4 |
| Freedland Cory S. | director | Jun 14, 2024 | AWARD | 7,700 | $42.59 | $327.9K | Form 4 |
| McMinn Rachel | director, officer: Chief Executive Officer | Mar 13, 2024 | AWARD | 93,282 | $36.06 | $3.4M | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 13, 2024 | AWARD | 53,900 | $36.06 | $1.9M | Form 4 |
| Cvijic Christine Mikail | President and CFO | Mar 13, 2024 | AWARD | 31,903 | — | — | Form 4 |
| Cobb Stuart | Chief Scientific Officer | Mar 13, 2024 | AWARD | 34,450 | $36.06 | $1.2M | Form 4 |
| Cobb Stuart | Chief Scientific Officer | Mar 13, 2024 | AWARD | 20,391 | — | — | Form 4 |
| BAKER BROS. ADVISORS LP | director, other: Former 10% Owner | Dec 18, 2023 | AWARD | 1,151,124 | — | — | Form 4 |
| BAKER BROS. ADVISORS LP | director, other: Former 10% Owner | Dec 18, 2023 | AWARD | 221,557 | — | — | Form 4 |
| BAKER BROS. ADVISORS LP | director, other: Former 10% Owner | Dec 18, 2023 | AWARD | 310,130 | — | — | Form 4 |
| BAKER BROS. ADVISORS LP | director, other: Former 10% Owner | Dec 18, 2023 | AWARD | 973,290 | — | — | Form 4 |
| BAKER BROS. ADVISORS LP | director, other: Former 10% Owner | Dec 18, 2023 | AWARD | 93,480 | — | — | Form 4 |
| BAKER BROS. ADVISORS LP | director, other: Former 10% Owner | Dec 18, 2023 | AWARD | 20,562 | — | — | Form 4 |
| BAKER BROS. ADVISORS LP | director, other: Former 10% Owner | Dec 18, 2023 | AWARD | 28,782 | — | — | Form 4 |
| BAKER BROS. ADVISORS LP | director, other: Former 10% Owner | Dec 18, 2023 | AWARD | 78,325 | — | — | Form 4 |